Form 4: Schrodinger Executive Receives Substantial Equity Grant Under Inducement Plan

Mannix Vartan Aklian, EVP and Chief Commercial Officer of Schrodinger, Inc., was granted 14,063 restricted stock units and options to purchase 84,375 shares of common stock as part of an inducement equity incentive plan.

Summary

• Mannix Vartan Aklian, the Executive Vice President, Chief Commercial Officer, and Global Head of Software Sales & Marketing at Schrodinger, Inc. (SDGR), received a significant equity grant on May 29, 2025.
• The grant includes 14,063 Restricted Stock Units (RSUs) and stock options for 84,375 shares of common stock.
• The RSUs were granted at a price of $0 and are scheduled to vest in equal installments on July 15, 2026, 2027, 2028, and 2029, contingent on Mr. Aklian's continued service.
• The stock options have an exercise price of $21.44 per share and will vest 25% on May 28, 2026, with the remaining portion vesting in equal monthly installments through May 28, 2029, also subject to continued service.
• Both the RSUs and stock options were granted under the Issuer's 2021 Inducement Equity Incentive Plan.

Sentiment

Score: 7

Explanation: The grant of significant equity to a key executive is generally positive as it aligns management's interests with shareholders and aids in retention. It reflects the company's commitment to its leadership team and their long-term contribution.

Positives

• The grant of significant equity to a key executive like Mannix Vartan Aklian aligns his long-term interests with those of the shareholders, incentivizing sustained performance.
• The grants are part of an 'Inducement Equity Incentive Plan,' which typically signifies a strategic move to attract, retain, or reward critical talent, reinforcing leadership stability.

Negatives

• No direct negatives are identified in this specific Form 4 filing, as it primarily reports a standard equity compensation event.

Risks

• The vesting of both RSUs and stock options is contingent upon the reporting person's continued service with the company, meaning the benefits are not guaranteed if employment ceases.
• The ultimate value realized from these equity grants is directly tied to the future performance and market price of Schrodinger, Inc.'s common stock, introducing market risk.

Future Outlook

This filing primarily reports a past equity grant transaction. The future outlook is tied to the vesting schedules of the granted RSUs and stock options, which are designed to incentivize the executive's long-term performance and continued service with Schrodinger, Inc. through 2029.

Industry Context

Equity grants, including Restricted Stock Units (RSUs) and stock options, are a standard and prevalent component of executive compensation packages across the technology, software, and biotechnology sectors. Inducement grants are particularly common for attracting or retaining senior talent, especially in competitive industries like computational drug discovery, where companies vie for top-tier leadership.

Comparison to Industry Standards

• Equity compensation, comprising RSUs and stock options, is a widely adopted practice for executive incentives in the technology and life sciences industries, aligning management's interests with shareholder value.
• The structure of vesting over several years is typical for long-term incentive plans, promoting executive retention and sustained performance.
• The size of the grant for an EVP, Chief Commercial Officer, and Global Head of Software Sales & Marketing would typically be benchmarked against similar roles at comparable publicly traded companies in the computational drug discovery or specialized software sectors, such as Dassault Systèmes (BIOVIA), Certara, or other biotech firms utilizing advanced computational platforms. Without specific peer group data, a direct quantitative comparison of the grant's size as 'better' or 'worse' is not feasible, but it represents a substantial commitment.

Related Party Transactions

• Grant of 14,063 Restricted Stock Units (RSUs) and 84,375 stock options to Mannix Vartan Aklian, an executive officer of Schrodinger, Inc., under the company's 2021 Inducement Equity Incentive Plan. This is a standard compensation arrangement between the company and a related party (executive).

Stakeholder Impact

• **Shareholders:** Potential positive impact through enhanced executive alignment with long-term company performance; potential future dilution from the issuance of shares upon vesting and exercise of the equity awards.
• **Employees:** May signal the company's commitment to attracting and retaining top talent, potentially boosting overall morale and confidence in leadership.
• **Management:** Mannix Vartan Aklian is strongly incentivized to drive company growth and stock price appreciation due to the significant equity stake.

Next Steps

• Continued service of Mannix Vartan Aklian with Schrodinger, Inc. to fulfill vesting conditions.
• Vesting of 14,063 RSUs in equal installments on July 15, 2026, 2027, 2028, and 2029.
• Vesting of 84,375 stock options, with 25% vesting on May 28, 2026, and the remainder monthly through May 28, 2029.
• Potential exercise of stock options by Mannix Vartan Aklian at or before their expiration date of May 29, 2035.

Key Dates

Keywords

Schrodinger Inc., SDGR, SEC Form 4, Equity Grant, Restricted Stock Units, RSUs, Stock Options, Executive Compensation, Inducement Plan, Mannix Vartan Aklian, Insider Transaction